Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Clinical trial of autologous differentiated adipocytes from stem cells derived from human adipose tissue.

Kim M., Kim I., Lee SK., Bang SI., Lim SY.

Clinical Trial with a reported sample of 17 on Scar, published in Dermatol Surg (2011) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Dermatol Surg (2011)
Country
United States
Reported sample size
17
Source database
PubMed
PMID
21575095
DOI
10.1111/j.1524-4725.2011.01765.x
Citations
40

Abstract (original English)

Background Adipose tissue-derived stem cells (ASCs) are considered to be a reliable cell source for the generation of adipose tissue because they can be differentiated into adipocytes. Previous data have indicated that adipogenic differentiation of ASCs before transplantation can enhance the regeneration of adipose tissue. Objective To evaluate the efficacy and safety of the use of autologous differentiated adipocytes for the treatment of depressed scars. Methods Autologous differentiated adipocytes were produced using well-established techniques, including the harvesting of stromal vascular fraction cells from lipoaspirates, expansion of ASCs, and differentiation into adipocytes. This was an open-label, dose-escalation study. Patients were given a subcutaneous injection of differentiated adipocytes and followed for 12 weeks. Results Thirty-one patients were injected with differentiated adipocytes. When the differentiated adipocytes were injected subcutaneously into depressed scars, the average recovery in volume was 74.6% at 12 weeks. Of 17 patients who completed the follow-up after determination of dose, seven were willing to enroll for extended follow-up. Long-term follow-up revealed that the recovery in volume at 12 weeks was maintained well for at least 1 year. There were no significant adverse events. Conclusions The use of autologous differentiated adipocytes can be a sa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdultCell DifferentiationCicatrixFemaleGene ExpressionHumansMaleStatistics, NonparametricStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research